Safety Alerts & Recalls

Search all Safety Alerts & Recalls

Latest Alerts

Early communication of ongoing safety review
The US FDA has issued an early communication about the ongoing review of new safety data for bisphosphanate medicines such as { drug_name }. The communication was issued by the FDA after it received reports of abnormal heart rhythms that may have been associated with bisphosphanate use. Upon initial review, it is unclear how this data should be interpreted. Therefore, FDA does not believe that healthcare providers or patients should change either their prescribing practices or their use of bisphosphonates at this time. For more information, please visit: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm070303.htm
Learn More

Public Health Advisory for Fentora (fentanyl buccal)
The US FDA today sent out a Public Heath Advisory and a Healthcare Professional Sheet regarding concerns over the use of Fentora (fentanyl buccal) tablets. The communication follows recent reports of serious side effects resulting from improper selection of patients, dosing, or improper product substitution. For more information, please contact your doctor - or visit: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm113690.htm
Learn More